Furthermore, AURKB overexpression has been implicated in paclitaxel resistance in NSCLC [44] and is associated with poor prognosis in hematological malignancies, such as acute lymphoblastic leukemia and acute myeloid leukemia [45]. This evidence concerns the gene AURKB and acute lymphoblastic leukemia.